Literature DB >> 23359969

[Effects of suxiao jiuxin pill on patients with acute coronary syndrome undergoing early percutaneous coronary intervention].

Xiao-Long Wang1, Yong-Ming Liu, Gu-Jing Zhu.   

Abstract

OBJECTIVE: To investigate the intervention effects of Suxiao Jiuxin Pill (SJP) on patients with acute coronary syndrome (ACS) undergoing early percutaneous coronary intervention (PCI).
METHODS: Sixty ACS patients were randomly assigned to the treatment group (treated by SJP and Western medicine) and the control group (treated by Western medicine alone), 30 in each group. Coronary arteriography and early PCI were performed in all patients. The effects of SJP on the blood flow rate, the collateral artery patency, and perioperative myocardial infarction incidence were observed.
RESULTS: The coronary blood flow rate was better in the treatment group than in the control group either pre- or post-PCI. [pre-PCI thrombolysis in myocardial infarction (TIMI) level III: 16/30 vs 11/30, P < 0.01; post-PCI TIMI level III: 14/14 vs 13/19, P < 0.05)]. In patients with ITMI level 0 - I , more patients in the treatment group had collateral artery protective function than those in the control group (5/6 vs 3/13, P < 0.05). The incidence of perioperative myocardial infarction was obviously lower in the treatment group than in the control group (8/30 vs 15/30, P < 0.05).
CONCLUSION: SJP could improve the pre- and post-PCI coronary artery flow rate, increase the collateral artery patency, and reduce the incidence of perioperative myocardial infarction of ACS patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23359969

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  7 in total

1.  Suxiao Jiuxin pill promotes exosome secretion from mouse cardiac mesenchymal stem cells in vitro.

Authors:  Xiao-Fen Ruan; Cheng-Wei Ju; Yan Shen; Yu-Tao Liu; Il-Man Kim; Hong Yu; Neal Weintraub; Xiao-Long Wang; Yaoliang Tang
Journal:  Acta Pharmacol Sin       Date:  2018-03-15       Impact factor: 6.150

2.  Exosomes from Suxiao Jiuxin pill-treated cardiac mesenchymal stem cells decrease H3K27 demethylase UTX expression in mouse cardiomyocytes in vitro.

Authors:  Xiao-Fen Ruan; Yong-Jun Li; Cheng-Wei Ju; Yan Shen; Wei Lei; Can Chen; Yang Li; Hong Yu; Yu-Tao Liu; Il-Man Kim; Xiao-Long Wang; Neal L Weintraub; Yaoliang Tang
Journal:  Acta Pharmacol Sin       Date:  2018-03-15       Impact factor: 6.150

3.  Suxiao Jiuxin Pill protects cardiomyocytes against mitochondrial injury and alters gene expression during ischemic injury.

Authors:  Xiaofen Ruan; Tiejun Chen; Xiaolong Wang; Yiping Li
Journal:  Exp Ther Med       Date:  2017-08-18       Impact factor: 2.447

4.  Traditional Chinese Medicine for Acute Myocardial Infarction in Western Medicine Hospitals in China.

Authors:  Erica S Spatz; Yongfei Wang; Adam L Beckman; Xuekun Wu; Yuan Lu; Xue Du; Jing Li; Xiao Xu; Patricia M Davidson; Frederick A Masoudi; John A Spertus; Harlan M Krumholz; Lixin Jiang
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-03

5.  Traditional Chinese Medicine Use in the Treatment of Acute Heart Failure in Western Medicine Hospitals in China: Analysis From the China PEACE Retrospective Heart Failure Study.

Authors:  Yuan Yu; Erica S Spatz; Qi Tan; Shuling Liu; Yuan Lu; Frederick A Masoudi; Wade L Schulz; Harlan M Krumholz; Jing Li
Journal:  J Am Heart Assoc       Date:  2019-07-31       Impact factor: 5.501

6.  Suxiao jiuxin pill induces potent relaxation and inhibition on contraction in human artery and the mechanism.

Authors:  Xiao-Yan Bai; Ping Zhang; Qin Yang; Xiao-Cheng Liu; Jun Wang; Yong-Ling Tong; Song-Jin Xiong; Li-Hua Liu; Lei Wang; Guo-Wei He
Journal:  Evid Based Complement Alternat Med       Date:  2014-04-07       Impact factor: 2.629

Review 7.  Efficacy of Suxiao Jiuxin Pill on Coronary Heart Disease: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Li Ren; Jie Wang; Ling Feng; Shuli Wang; Jun Li
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-27       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.